Dilafor

Executive Summary

Dilafor AB is a Swedish biopharmaceutical company developing tafoxiparin, a novel heparan sulfate mimetic designed to reduce maternal and fetal complications during labor by priming the cervix and myometrium for a more natural and efficient process. Founded in 2008 and based on foundational research from Karolinska Institutet and Lund University, Dilafor is currently in the pre-clinical stage, aiming to address significant unmet needs in obstetrics. The company's lead candidate, tafoxiparin, has demonstrated promising safety and efficacy signals in earlier studies, and Dilafor is preparing to advance into clinical development. With a focused pipeline and a clear therapeutic rationale, the company represents an early-stage opportunity in the women's health space. However, given its pre-clinical status, significant clinical and regulatory risks remain. The conviction score reflects the early stage but also the potential of the platform.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Trial Initiation65% success
• Q2 2027Partnership or Licensing Deal40% success
• Q3 2026Preclinical Proof-of-Concept Data Publication80% success